FDA Requests Public Input for Ibogaine Clinical Trial Design

The U.S. FDA has issued a Request for Information (RFI) to gather public input on designing early-phase clinical trials for ibogaine drug products. This initiative supports a broader federal effort to accelerate research into psychedelic medicine for conditions like opioid use disorder and PTSD, while also addressing significant safety concerns associated with ibogaine.